<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338647</url>
  </required_header>
  <id_info>
    <org_study_id>UAarhus HCC</org_study_id>
    <nct_id>NCT03338647</nct_id>
  </id_info>
  <brief_title>SBRT or TACE for Advanced HCC</brief_title>
  <official_title>Randomized Study of Stereotactic Body Radiation Therapy (SBRT) Versus Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Atomic Energy Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study of stereotactic body radiation therapyRANDOMIZED STUDY OF STER (SBRT) versus
      transarterial chemoembolization (TACE) in locally advanced hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression (total of local, intra- and extrahepatic)</measure>
    <time_frame>1 year</time_frame>
    <description>Modified RECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>3 months</time_frame>
    <description>Modified RESIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control of treated tumor</measure>
    <time_frame>1 year</time_frame>
    <description>Modified RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrahepatic failure</measure>
    <time_frame>1 year</time_frame>
    <description>Intrahepatic failure (more than 1 cm away)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrahepatic failure</measure>
    <time_frame>1 year</time_frame>
    <description>Modified RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Tox CTC Ver 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-benefit</measure>
    <time_frame>1 year</time_frame>
    <description>$ spend on hospitalization and treatment of complications after the treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transarterial chemoembolization with drug eluted beads or doxorubicin/lipoidol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic radiation therapy with risk adapted dose prescription</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DEB</intervention_name>
    <description>Infusion of DEB or doxorubin/lipiodol through catheter in the hepatic artery</description>
    <arm_group_label>TACE</arm_group_label>
    <other_name>doxorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>High precision radiation therapy to the liver tumor(s)</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCC (biopsy or radiological diagnostic (&gt;1 cm, enhancing in arterial phase and
             wash-out in later phases).

          -  Number of lesions: not more than 3 lesions

          -  Lesion size: up to 10 cm for a single lesion (and up to 10 cm cumulative diameter, if
             there is more than 1 lesion)

          -  Child-Pugh A or B (&lt;7) on examination within 6 weeks prior to study entry

          -  BCLC Stage A/B

          -  Must be fit (eligible) for SBRT and TACE

          -  Unsuitable/unwilling for resection or transplant or radiofrequency ablation (RFA) or
             if these options are not available

          -  Distance between GTV (lesion) and luminal structures (including esophagus, stomach,
             duodenum, small or large bowel) is &gt;10 mm

          -  All blood work obtained within 2 weeks prior to study entry with adequate organ
             function defined as follows:

               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3

               -  Platelets ≥50,000 cells/mm3

               -  Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to
                  achieve Hgb ≥ 8.0 g/dl is acceptable.)

               -  Total bilirubin &lt; 2 mg/dL

               -  Prothrombin time/INR &lt; 1.4 (unless on Coumadin/Warfarin)

               -  Albumin ≥ 28 g/L

               -  AST (and ALT) &lt; 5 times ULN

               -  Serum creatinine ≤ ULN or creatinine clearance ≥ 60 mL/min

               -  Left-ventricular ejection fraction &gt;50% (cardiac ejection fraction should be
                  measured in case of history of cardio-vascular disease.

               -  May have had previous surgery, ethanol injection and RFA to the liver

        Exclusion Criteria:

          -  • Not suitable for clinical trial or follow-up

               -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease
                  free for a minimum of 2 years (Note that carcinoma in situ of the breast, oral
                  cavity, or cervix are all permissible). No active cancer therapy.

               -  Unsuitable for or refractory to transarterial hepatic chemo-embolization (TACE)
                  Raoul et al (2011)

                    -  Non-enhancing HCC on CT or CT-angio or

                    -  Portal vein thrombosis/macroscopic venous invasion

               -  Arterio-portal and arterio-venous fistulas observed on pre-study imaging (if it
                  is found during the TACE, the fistula may be embolized before injection of the
                  drug).

               -  Evidence of metastatic disease including nodal or distant metastases.

               -  Previous TACE or radiation to the liver (including SIRT)

               -  Life-threatening condition (including untreated HIV and active hepatitis B/C)

                    -  Detectable HBeAg and HBV viral load &gt; 20,000 IU/mL or

                    -  HBeAg-negative chronic hepatitis B and HBV viral load &gt;2,000 IU/mL

                    -  If HBV-DNA copy is higher than 500 copies/ml, anti-viral therapy, such as
                       Entecavir followed by observation for 2 weeks.

                    -  If anti-HCV antibody is positive (may be false positive) and increased HCV
                       viral load indicating active disease. Active HCV should be treated
                       sufficiently before inclusion in the study. Below 2 million copies per
                       milliliter (mL) is related to chronic hepatitis C that does not need
                       antiviral therapy.

                    -  Patients with active hepatitis B or C should be on treatment for at least 4
                       weeks before inclusion in the trial

               -  On sorafenib or other antineplastic drug therapy within 7 days before inclusion
                  (not accepted until time of progression).

               -  Pregnancy or women of childbearing potential require a negative pregnancy test
                  within 28 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Morten Høyer, PhD</last_name>
    <phone>+45 23282823</phone>
    <email>hoyer@aarhus.rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medanta</name>
      <address>
        <city>Delhi</city>
        <state>NCT</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tejinder Kataria, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic body radiation therapy</keyword>
  <keyword>transarterial chemoembolization</keyword>
  <keyword>SBRT</keyword>
  <keyword>TACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

